Editas Medicine (NASDAQ:EDIT) Azioni

Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Editas Medicine Inc

News

Management

EDIT

Editas Medicine CFO Erick Lucera To Step Down To Pursue Another Opportunity; Amy Parison Appointed As CFO

Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.38) by 44.74 percent. This is a 139.13 percent decrease over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $30.604 million which missed the analyst consensus estimate of $32.230 million by 5.04 percent. This is a 49.04 percent decrease over sales of $60.050 million the same period last year.

Earnings

Earnings Misses

Editas Medicine Q4 2024 GAAP EPS $(0.55) Misses $(0.38) Estimate, Sales $30.604M Miss $32.230M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Full Truck Alliance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $419.04 million. 
• Brown Forman Inc Class B Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is projected to report quarterly earnings at $0.46 per share on revenue of $1.07 billion. 
• CLPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPS#NASDAQ">CLPS</a>) is estimated to report earnings for its first quarter. 
• EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) is expected to report quarterly loss at $0.48 per share on revenue of $11.02 million. 
• Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $39.59 million. 
• Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) is expected to report quarterly loss at $0.58 per share on revenue of $19.97 million. 
• Hydrofarm Holdings Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYFM#NASDAQ">HYFM</a>) is likely to report quarterly loss at $2.00 per share on revenue of $41.10 million. 
• Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $300 thousand. 
• Global Ship Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>) is projected to report quarterly earnings at $2.54 per share on revenue of $171.17 million. 
• Broadwind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWEN#NASDAQ">BWEN</a>) is expected to report quarterly loss at $0.07 per share on revenue of $31.90 million. 
• Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $1.97 billion. 
• Caesarstone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTE#NASDAQ">CSTE</a>) is expected to report quarterly loss at $0.23 per share on revenue of $99.40 million. 
• REV Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $492.77 million. 
• Daktronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAKT#NASDAQ">DAKT</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $183.46 million. 
• Campbell`s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) is likely to report quarterly earnings at $0.73 per share on revenue of $2.74 billion. 
• Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $110.00 million. 
• VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $30.41 million. 
• OppFi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPFI#NYSE">OPFI</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $133.50 million. 
• Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $90.36 million. 
• Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) is projected to report quarterly earnings at $1.35 per share on revenue of $201.09 million. 
• SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) is projected to report quarterly loss at $0.03 per share on revenue of $37.78 million. 
• Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $500 thousand. 
• Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is likely to report quarterly earnings at $3.29 per share on revenue of $1.52 billion. 
• Brown Forman Inc Class A Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is estimated to report earnings for its third quarter. 
• Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) is projected to report quarterly earnings at $0.73 per share on revenue of $2.32 billion. 
• Stratasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $149.88 million. 
<h3>Companies Reporting After The Bell</h3>
• Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) is projected to report quarterly earnings at $0.69 per share on revenue of $635.56 million. 
• Ring Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REI#AMEX">REI</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $86.72 million. 
• Vermilion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VET#NYSE">VET</a>) is likely to report quarterly earnings at $1.67 per share on revenue of $507.35 million. 
• Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $62.00 million. 
• FRP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPH#NASDAQ">FRPH</a>) is likely to report earnings for its fourth quarter. 
• MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $172.52 million. 
• Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) is likely to report quarterly earnings at $1.09 per share on revenue of $290.30 million. 
• Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is estimated to report quarterly earnings at $0.21 per share on revenue of $128.69 million. 
• CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $102.50 million. 
• Alto Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTO#NASDAQ">ALTO</a>) is projected to report quarterly loss at $0.11 per share on revenue of $222.81 million. 
• Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) is projected to report quarterly loss at $481.50 per share on revenue of $400 thousand. 
• Park-Ohio Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKOH#NASDAQ">PKOH</a>) is projected to report quarterly earnings at $0.62 per share on revenue of $405.85 million. 
• NACCO Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NC#NYSE">NC</a>) is expected to report earnings for its fourth quarter. 
• Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) is projected to report quarterly loss at $0.06 per share on revenue of $2.50 million. 
• Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) is likely to report quarterly loss at $0.09 per share on revenue of $20.75 million. 
• Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) is projected to report quarterly loss at $0.25 per share on revenue of $489.80 million. 
• Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $112.77 million. 
• Methode Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) is projected to report quarterly loss at $0.10 per share on revenue of $262.60 million. 
• Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) is likely to report quarterly loss at $0.17 per share on revenue of $612.38 million. 
• NN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNBR#NASDAQ">NNBR</a>) is likely to report quarterly loss at $0.06 per share on revenue of $108.60 million. 
• Climb Global Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>) is likely to report quarterly earnings at $1.12 per share on revenue of $114.37 million. 
• Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) is expected to report quarterly loss at $0.13 per share on revenue of $13.13 million. 
• Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) is likely to report quarterly loss at $0.20 per share on revenue of $6.12 million. 
• Aware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWRE#NASDAQ">AWRE</a>) is likely to report earnings for its fourth quarter. 
• LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) is likely to report quarterly loss at $0.05 per share on revenue of $68.13 million. 
• TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $26.68 million. 
• Allient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNT#NASDAQ">ALNT</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $119.71 million. 
• ACRES Commercial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACR#NYSE">ACR</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $22.75 million. 
• Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $20.29 million. 
• Rayonier Adv Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAM#NYSE">RYAM</a>) is expected to report quarterly loss at $0.19 per share on revenue of $418.50 million. 
• Amplify Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $76.54 million. 
• Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $90.74 million. 
• LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) is estimated to report quarterly earnings at $0.63 per share on revenue of $237.32 million. 
• Sleep Number (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $389.75 million. 
• Fortuna Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $308.00 million. 
• Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is expected to report earnings for its fourth quarter. 
• Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $259.11 million. 
• Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $12.70 million. 
• Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $45.20 million. 
• Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) is expected to report quarterly earnings at $1.58 per share on revenue of $699.27 million. 
• Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) is estimated to report earnings for its fourth quarter. 
• MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $519.45 million. 
• Arq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQ#NASDAQ">ARQ</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $25.70 million. 
• Nine Energy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $135.00 million. 
• Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) is estimated to report quarterly earnings at $0.59 per share on revenue of $1.80 billion. 
• Descartes Systems Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) is likely to report quarterly earnings at $0.56 per share on revenue of $169.38 million. 
• Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $323.08 million. 
• LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $38.04 million. 
• Riley Exploration Permian (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REPX#AMEX">REPX</a>) is likely to report quarterly earnings at $1.64 per share on revenue of $105.49 million. 
• Pampa Energia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAM#NYSE">PAM</a>) is expected to report quarterly earnings at $0.72 per share on revenue of $450.71 million. 
• GeoPark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRK#NYSE">GPRK</a>) is expected to report quarterly earnings at $0.80 per share on revenue of $168.00 million. 
• Orion Office REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONL#NYSE">ONL</a>) is likely to report earnings for its fourth quarter. 
• Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) is likely to report quarterly earnings at $0.13 per share on revenue of $19.62 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNT

ALTG

ALTO

AMPY

AQST

ARBE

AWRE

BALY

BBAR

BWEN

CLMB

CLPS

CMPO

CSTE

CULP

DAKT

DSGX

EHAB

EYPT

FRGE

FRPH

GPRK

GRND

GWRS

HYFM

INVE

KMDA

LPSN

MRVL

NEXN

NINE

NNBR

OCGN

OPFI

PKOH

REPX

REVG

RGTI

RSKD

RYAM

SGHT

SMRT

SNBR

SSYS

SVCO

TPVG

TREE

VBNK

VEEV

VSCO

YEXT

ZYME

Earnings Scheduled For March 5, 2025

Editas Medicine's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NYSE">EDIT</a>) short percent of float has fallen 10.76% since its last report. The company recently reported that it has 17.09 million shares sold short, which is 26.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Editas Medicine Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740508228_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Editas Medicine has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Editas Medicine's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Editas Medicine's peer group average for short interest as a percentage of float is 8.26%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Editas Medicine's Recent Short Interest

<ul>
<li>Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia</li>
<li>Achieved in vivo editing of liver cells in non-human primates and in vivo delivery to two additional cell types in humanized mice</li>
<li>Anticipated 2025 milestones include: declare two in vivo development candidates, one in HSCs and one in liver; present further in vivo HSC data; present in vivo data in one liver indication; establish one additional target cell type/tissue; and continue to derive revenue through sublicensing foundational IP</li>
<li>Strategic priorities through 2027 include: submit at least one IND/CTA; achieve human in vivo proof of concept in HSC editing for the treatment of sickle cell disease and beta thalassemia; and commence late-stage trial of at least one asset</li>
<li>Strong financial position with operational runway into Q2 2027</li>
<li>Company to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15 at 11:15 a.m. PST &nbsp;</li>
</ul>
CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced its three-year strategic priorities, anticipated 2025 key milestones, and new in vivo preclinical proof of concept data in non-human primates editing hematopoietic stem cells (HSCs) and liver cells and in vivo delivery data in humanized mice to two additional target cell types.

Biotech

General

Editas Medicine Announces In Vivo Preclinical Proof Of Concept In HSC And Liver Cells, 2025 Milestones, And Strategic Priorities Through 2027 With Operational Runway Into Q2 2027

Editas Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) announced last week a strategic realignment to focus on in <a href="https://www.benzinga.com/general/biotech/24/12/42480865/editas-medicine-realigns-strategy-to-focus-on-in-vivo-gene-editing-targets-human-proof-of-concept-by-2026" target="_blank" rel="noreferrer noopener">vivo gene editing</a>.
The shift is designed to optimize costs, extend its cash runway into the second quarter of 2027, and accelerate its progress toward achieving human proof of concept within two years.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42170987/editas-medicine-downgraded-analyst-sees-limited-near-term-catalysts" rel="noreferrer noopener">Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts</a>
JPMorgan spoke with Editas management. The analyst said that, overall, they were surprised by the timing of the restructuring. While there are personnel and legal considerations, the pivot would be better received if delivered in a single step, the analyst wrote.
JPMorgan highlighted the strategic move to prioritize in vivo programs, but noted that clarity is needed on the next steps and the timeline for initial human proof-of-concept results.
Until more visibility is gained, investors may remain cautious, keeping Editas Medicine shares trading within a limited range compared to peers in the coverage.
The analyst saw significant value embedded in its technical expertise and IP estate. However, the next major inflection point in the stock is still a way away, and investors will want to see the first clinical proof of concept before returning to the story.
As such, Editas Medicine shares will underperform relative to other names in JPMorgan&#8217;s coverage universe for now. The analyst downgraded the rating to Underweight from Neutral.
The recent strategic updates, including workforce cuts and management/board departures, may raise concerns about Editas Medicine&#8217;s shift toward in vivo development. JP Morgan added that these changes could suggest further adjustments to its development strategy in the future.
EDIT Price Action: Editas Medicine stock is up 2.36% at $1.52 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42514960/whats-going-on-illumina-stock-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Illumina Stock On Monday?</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock.com

Analyst Color

Downgrades

Health Care

Analyst Ratings

JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution

Evercore ISI Group analyst Liisa Bayko maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Outperform and lowers the price target from $7 to $5.

Price Target

Evercore ISI Group Maintains Outperform on Editas Medicine, Lowers Price Target to $5

JP Morgan analyst Brian Cheng downgrades Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) from Neutral to Underweight.

JP Morgan Downgrades Editas Medicine to Underweight

RBC Capital analyst Luca Issi maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Sector Perform and lowers the price target from $5 to $4.

RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $4

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays slashed the price target for The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) from $23 to $17. Barclays analyst Nicholas Campanella maintained an Overweight rating. AES shares closed at $13.41 on Thursday. See how other analysts view this stock.</li>
<li>Morgan Stanley raised the price target for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from $310 to $435. Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating. RH shares closed at $381.38 on Thursday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt boosted the price target for Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) from $75 to $94. Rosenblatt analyst Mike Genovese maintained a Neutral rating. Ciena shares closed at $84.52 on Thursday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) price target from $82 to $80. Morgan Stanley analyst Alex Straton maintained an Equal-Weight rating. Nike shares settled at $77.96 on Thursday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Tigress Financial raised Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) price target from $86 to $115. Tigress Financial analyst Ivan Feinseth maintained a Buy rating. Walmart shares closed at $93.88 on Thursday. <a href="https://www.benzinga.com/quote/WMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) price target from $188 to $156. JP Morgan analyst Michael Rehaut downgraded the stock from Neutral to Underweight. D.R. Horton shares closed at $151.21 on Thursday.  <a href="https://www.benzinga.com/quote/DHI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut Editas Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) price target from $11 to $3. Stifel analyst Dae Gon Ha downgraded the stock from Buy to Hold. Editas Medicine shares closed at $1.89 on Thursday. See how other analysts view this stock.</li>
<li>Deutsche Bank boosted the price target for Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) from $190 to $240. Deutsche Bank analyst Ross Seymore maintained a Buy rating. Broadcom shares settled at $180.66 on Thursday. <a href="https://www.benzinga.com/quote/AVGO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan slashed Meritage Homes Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) price target from $220 to $197. JP Morgan analyst Michael Rehaut downgraded the stock from Overweight to Neutral. Meritage Homes shares closed at $177.45 on Thursday. <a href="https://www.benzinga.com/quote/MTH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays raised Marriott Vacations Worldwide Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) price target from $97 to $116. Barclays analyst Brandt Montour upgraded the stock from Equal-Weight to Overweight. Marriott Vacations shares closed at $94.85 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>

Markets

AVGO

CIEN

Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stifel analyst Dae Gon Ha downgraded the rating for Editas Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) from Buy to Hold and lowered the price target from $11 to $3. Editas Medicine shares closed at $1.89 on Thursday. See how other analysts view this stock.</li>
<li>Mizuho analyst Siti Panigrahi downgraded the rating for RingCentral, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) from Outperform to Neutral and maintained the price target of $42. RingCentral shares closed at $41.35 on Thursday. <a href="https://www.benzinga.com/quote/RNG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Michael Rehaut downgraded Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) from Overweight to Neutral and lowered the price target from $166 to $150. Toll Brothers shares closed at $138.46 on Thursday. <a href="https://www.benzinga.com/quote/TOL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird analyst Michael Halloran downgraded the rating for Nordson Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) from Outperform to Neutral and slashed the price target from $294 to $237. Nordson shares closed at $229.11 on Thursday. <a href="https://www.benzinga.com/quote/NDSN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Brandt Montour downgraded Viking Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) from Overweight to Equal-Weight and maintained the price target of $49. Viking Holdings shares closed at $46.18 on Thursday. <a href="https://www.benzinga.com/quote/VIK/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying TOL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13100359/image-117-1024x586.png" alt="" class="wp-image-691577" style="width:656px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13100359/image-117-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13100359/image-117-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13100359/image-117-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13100359/image-117.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>

NDSN

This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

WIIM

Editas Medicine shares are trading lower after Stifel and Chardan Capital downgraded the stock and multiple firms cut their respective price targets.

Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Equal-Weight and lowers the price target from $5 to $3.

Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $3

Chardan Capital analyst Geulah Livshits downgrades Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) from Buy to Neutral.

Chardan Capital Downgrades Editas Medicine to Neutral

Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Outperform and lowers the price target from $10 to $8.

Baird Maintains Outperform on Editas Medicine, Lowers Price Target to $8

On Thursday, Editas Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) announced a strategic realignment to focus on in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42471563/editas-medicine-announces-strategic-transition-to-in-vivo-gene-editing-company-with-intent-to-achi" rel="noreferrer noopener">vivo gene editing</a>.
In vivo refers to studies or experiments conducted on living organisms or cells instead of dead organisms or tissue extracts.&nbsp;The opposite of in vivo is in vitro, which means outside the body or in a laboratory.
The shift is designed to optimize costs, extend its cash runway into the second quarter of 2027, and accelerate its progress toward achieving human proof of concept within two years.
The transition follows recent in vivo preclinical research advancements, including proof of concept in multiple tissue types.
For hematopoietic stem cells (HSCs), Editas demonstrated ~40% editing of the HBG1/2 promoter using a proprietary targeted lipid nanoparticle (tLNP).
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42170987/editas-medicine-downgraded-analyst-sees-limited-near-term-catalysts" rel="noreferrer noopener">Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts</a>
The single-dose delivery of Cas12a editing machinery directly to human HSCs in mice yielded significant functional outcomes. Within one month, human red blood cells expressed fetal hemoglobin (HbF) at an average of 20%.
The achievement builds on validated HBG1/2 biology from the RUBY trial with Editas&#8217; <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42394977/editas-medicine-reports-updated-clinical-data-from-the-ruby-trial-of-reni-cel-in-patients-with-sev" rel="noreferrer noopener">reni-cel program</a>.
In liver applications, Editas achieved high-efficiency gene editing in non-human primates in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41439513/editas-medicine-and-genevant-sciences-to-collaborate-to-develop-novel-mrna-lnp-gene-editing-therap" rel="noreferrer noopener">collaboration with Genevant</a>.
The company will share detailed preclinical data and development timelines in early 2025.
As part of its transition, Editas announced a workforce reduction, eliminating approximately 65% of its employees over the next six months.
This includes several leadership team members, such as Chief Medical Officer Baisong Mei. The company stated that these changes align with its renewed focus on in vivo therapies.
By restructuring operations and prioritizing its in vivo platform, Editas aims to create a more streamlined and efficient organization.
Cash, cash equivalents, and marketable securities as of September&nbsp;30, 2024, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41710488/editas-medicine-announces-third-quarter-2024-results-and-business-updates" rel="noreferrer noopener">were $265.1&nbsp;million</a>.
The company expects the existing cash, cash equivalents, and marketable securities, the upfront cash payment from DRI, and the retained portions of the payments payable under the license agreement with Vertex to fund operating expenses and capital expenditures into the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41176304/editas-medicine-announces-50-million-monetization-financing-with-dri-healthcare-trust" rel="noreferrer noopener">second quarter&nbsp;of&nbsp;2026</a>.
Price Action: At last check on Friday, EDIT stock was down 8.99% at $1.72 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42470172/what-does-dental-player-pattersons-41-billion-deal-mean-for-other-players-analyst-outlines" target="_blank" rel="noreferrer noopener">What Does Dental Player Patterson&#8217;s $4.1 Billion Deal Mean For Other Players?</a></li>
</ul>

Movers

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Stifel analyst Dae Gon Ha downgrades Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) from Buy to Hold and lowers the price target from $11 to $3.

Stifel Downgrades Editas Medicine to Hold, Lowers Price Target to $3

Editas Medicine shares are trading higher after the company announced plans to transition to an in vivo focus and initiated a reduction in headcount, aiming to eliminate approximately 65% of its workforce over the next six months.

Editas Medicine Initiates Cost Savings Measures And Reduction In Headcount To Align Workforce And Resources To In Vivo Pipeline, Extending Cash Runway Into Q2 2027

Editas Medicine Says Ending Development Of Reni-Cel After Extensive Search Did Not Yield A Commercial Partner

Press Releases

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Comments

Editas Medicine

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO